Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

Next Previous
Search
Trial Profile

A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asparaginase (Primary) ; Asparaginase (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Ixazomib (Primary) ; Vincristine (Primary) ; Crisantaspase; Crisantaspase
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 20 Feb 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
    • 20 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top